After a strong year of approvals for gene therapies, we saw both the preclinical and clinical pipelines build, with 600+ and 250+ active trials in each category, respectively. The complex and difficult-to-predict immune response in animal models and patients however threatens developers with serious safety concerns bringing these trials to a halt.
Decision makers from leading drug developers told us they had little visibility into which contract service providers have the experience and expertise to meet these demands. After extensive research with biopharma leaders, it is clear there remains a clear need for two main services:
- Appropriate animal models to test and understand immune-related safety and efficacy profiles
- Effective, validated, and quick assay development tools to effectively measure and monitor immunogenicity
Partnering with the 4th Annual Gene Therapy Immunogenicity Summit brought you closer to 130+ immunology, bioanalytical, toxicology, preclinical, clinical, translational and scientist leaders in the field, actively seeking networking and collaborating opportunities to overcome the challenges they face.
Your brand, your message, and your reputation – showcased in front of the leading experts in the gene therapy field.